Breaking News, Trials & Filings

Trials & Filings in Brief: Sept. 27, 2013

CSL Behring, Durata, Novartis, Zalicus

By: Gil Roth

President, Pharma & Biopharma Outsourcing Association

Filings CSL Behring’s Hizentra cleared to treat PID in Japan . . . read more Durata files NDA for ABSSSI treatment . . . read more Zalicus gets orphan designation for Z160 . . . read more Post-Approval Good data for Novartis’ Lucentis . . . read more...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters